Cantillon Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

Cantillon Capital Management’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-769,698	Closed	-$378M	–	37
2026 Q1	$378M	Sell	769,698 -103,624	-12%	-$56.2M	2.51%	16
2025 Q4	$506M	Buy	873,322 +6,552	+0.8%	+$3.71M	2.74%	13
2025 Q3	$420M	Sell	866,770 -9,495	-1%	-$4.42M	2.31%	22
2025 Q2	$355M	Sell	876,265 -25,508	-3%	-$10.7M	2.05%	24
2025 Q1	$449M	Sell	901,773 -28,097	-3%	-$15.2M	2.91%	13
2024 Q4	$484M	Buy	929,870 +130,870	+16%	+$72M	2.92%	14
2024 Q3	$494M	Sell	799,000 -23,838	-3%	-$14.1M	3.02%	13
2024 Q2	$455M	Sell	822,838 -41,876	-5%	-$24M	3.04%	11
2024 Q1	$503M	Sell	864,714 -17,303	-2%	-$9.71M	3.16%	11
2023 Q4	$468M	Sell	882,017 -21,746	-2%	-$10.5M	3.13%	12
2023 Q3	$457M	Sell	903,763 -3,451	-0.4%	-$1.84M	3.39%	8
2023 Q2	$473M	Buy	907,214 +87,092	+11%	+$47M	3.31%	9
2023 Q1	$473M	Sell	820,122 -14,827	-2%	-$8.36M	3.85%	5
2022 Q4	$460M	Sell	834,949 -16,490	-2%	-$8.74M	3.89%	7
2022 Q3	$432M	Sell	851,439 -6,767	-0.8%	-$3.79M	3.91%	5
2022 Q2	$466M	Sell	858,206 -4,695	-0.5%	-$2.58M	3.89%	6
2022 Q1	$510M	Buy	862,901 +24,611	+3%	+$14.1M	3.64%	7
2021 Q4	$559M	Sell	838,290 -62,921	-7%	-$39.3M	3.69%	5
2021 Q3	$515M	Sell	901,211 -15,459	-2%	-$8.48M	3.51%	8
2021 Q2	$462M	Sell	916,670 -12,734	-1%	-$6.01M	3.11%	12
2021 Q1	$424M	Sell	929,404 -34,796	-4%	-$16.6M	3.09%	12
2020 Q4	$449M	Sell	964,200 -4,781	-0.5%	-$2.24M	3.37%	13
2020 Q3	$428M	Sell	968,981 -11,867	-1%	-$4.9M	3.58%	11
2020 Q2	$355M	Buy	980,848 +10,323	+1%	+$3.46M	3.09%	14
2020 Q1	$275M	Sell	970,525 -1,256	-0.1%	-$396K	3.04%	15
2019 Q4	$316M	Sell	971,781 -21,083	-2%	-$6.39M	2.94%	17
2019 Q3	$289M	Sell	992,864 -8,117	-0.8%	-$2.32M	2.81%	17
2019 Q2	$294M	Sell	1,000,981 -20,764	-2%	-$5.72M	2.97%	18
2019 Q1	$280M	Sell	1,021,745 -3,185	-0.3%	-$793K	2.97%	17
2018 Q4	$229M	Buy	1,024,930 +489,081	+91%	+$115M	2.77%	17
2018 Q3	$131M	Buy	+535,849	New	+$123M	1.47%	31

Other funds holding TMO

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Cantillon Capital Management's TMO Position: Q2 2026 in Review

Cantillon Capital Management sold out of Thermo Fisher Scientific (TMO) in Q2 2026, closing a stake of 769,698 shares — an estimated $378M sold.

Cantillon Capital Management first reported a position in TMO in Q3 2018 and held it in 31 quarters. The position peaked at $559M in Q4 2021. 1,515 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

Cantillon Capital Management reported no remaining Thermo Fisher Scientific position as of Q2 2026 after selling out during the quarter.
Cantillon Capital Management sold 769,698 Thermo Fisher Scientific shares in Q2 2026, an estimated $378M.
Cantillon Capital Management first reported a position in Thermo Fisher Scientific in Q3 2018 and held it in 31 quarters.
Cantillon Capital Management's Thermo Fisher Scientific position peaked at $559M in Q4 2021.
1,515 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Cantillon Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.